Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a ... Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. Mehr anzeigen
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 312,000 shares of its common stock...
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 72,000 shares of Geron...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal...
Analyses pooling data from IMerge Phase 2, Phase 3 and the QTc substudy suggest patients who were ESA ineligible or who had prior treatment with luspatercept or lenalidomide experienced clinical...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7th...
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 1,017,000 shares of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.04 | 1.35593220339 | 2.95 | 3.12 | 2.895 | 6080782 | 2.98710584 | CS |
| 4 | -0.35 | -10.4790419162 | 3.34 | 3.68 | 2.8 | 12019365 | 3.24847635 | CS |
| 12 | -1.09 | -26.7156862745 | 4.08 | 4.5 | 2.8 | 10863317 | 3.64973694 | CS |
| 26 | -1.71 | -36.3829787234 | 4.7 | 4.89 | 2.8 | 9435620 | 4.03892039 | CS |
| 52 | 0.82 | 37.7880184332 | 2.17 | 5.34 | 1.64 | 10818168 | 3.73929437 | CS |
| 156 | 1.92 | 179.439252336 | 1.07 | 5.34 | 0.9899 | 6871307 | 3.09930572 | CS |
| 260 | 1.64 | 121.481481481 | 1.35 | 5.34 | 0.75 | 5436467 | 2.74545473 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
